Development and Validation of a Nomogram for Predicting Postoperative Distant Metastasis in Patients with Cervical Cancer

Weihong Zeng
Lishan Huang
Haihong Lin
Ru Pan
Haohang Liu
Jizhong Wen
Ye Liang
Haikun Yang

Corresponding Author: Haikun Yang, e-mail: haikunyang2003@163.com

Financial support: None declared
Conflict of interest: None declared

Background: Cervical cancer is the fourth most commonly diagnosed malignant neoplasm among women worldwide. Despite improvements in treatment, the rate of postoperative metastasis remains a problem. Nomograms have been used to predict risk of tumor metastasis. We designed a nomogram to predict postoperative distant metastasis among cervical cancer patients, based on the SEER database, and estimated the performance of the nomogram by internal and external validations.

Material/Methods: We included 6421 participants and divided them into training (n=4495) and testing (n=1926) sets. Multivariate logistic regression was used to explore predictors. The nomogram's predictive value was assessed by internal (testing set) and external (561 Chinese patients) validations. The receiver operating characteristic curve (ROC) was plotted, and the area under the curve (AUC) value was calculated to evaluate the nomogram's discrimination. The nomogram's calibration was assessed via the Hosmer-Lemeshow test and calibration curve.

Results: Histologic type, T stage, treatment, tumor size, and positive lymph node were identified as independent predictors of postoperative distant metastasis in surgical patients (P<0.05). The developed nomogram had an AUC of 0.866 (95% CI: 0.844 to 0.888). The AUC and the chi-square for the Hosmer-Lemeshow test of the nomogram were 0.847 (95% CI: 0.807 to 0.888) and 11.292, respectively, (P>0.05) in the internal validation, and were 0.626 (95% CI: 0.548 to 0.704) and 316.53, respectively, (P<0.05) in the external validation.

Conclusions: Our nomogram showed a good predictive performance for postoperative distant metastasis in cervical cancer patients based on the SEER database. It remains to be determined if it is applicable to other populations.

Keywords: Database • Nomograms • Uterine Cervical Neoplasms • Validation Study

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/933379

Department of Gynaecology, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, Guangdong, PR China

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background

Cervical cancer is the fourth most commonly diagnosed malignant neoplasm among women worldwide [1]. It was estimated that 569,847 new cervical cancer cases and 311,365 deaths occur each year [2]. Despite significant improvements in the treatment of cervical cancer by surgical resection, the rate of postoperative distant metastasis remains an intractable problem, which has been proved to be associated with cervical cancer-related death [3,4]. Therefore, it is vital for physicians to be able to predict postoperative distant metastasis to improve the prognosis of cervical cancer patients.

Some predictors, such as pelvic lymph node metastasis [5], histologic type [6,7], and tumor size [8,9], have been revealed in previous studies to be associated with high risk of recurrence in patients with cervical cancer after surgical therapy. Several postoperative nomograms have been developed to predict the risk of recurrence in early-stage cervical cancer [10-13]. Moreover, Lee et al built a scoring system based on histologic type, the number of positive nodes, and surgical staging, which was used to assess the risk of distant recurrence in cervical cancer patients after radical surgery [14]. Although some investigations have focused on the predictive factors of distant metastasis in cervical cancer patients [15-17], scant evidence is available on models to predict the risk of distant metastasis after surgery in patients with cervical cancer. Je et al proposed a nomogram based on 1069 Korean patients with uterine cervical carcinoma undergoing postoperative radiotherapy to predict distant metastasis risks in 2014 [18], which was successfully validated among 109 cervical cancer patients from 3 branch hospitals of the Korea University Medical Center in 2017 [19]. Nomograms have been used to predict the possibility of tumor metastasis, and can visualize complex regression equations to make predictive results more intuitive and convenient for clinicians to use [20-22]. At present, no nomograms are available for other countries except Korea to predict the postoperative distant metastasis of cervical cancer.

In the present study, we constructed a clinical nomogram to predict postoperative distant metastasis among cervical cancer patients based on the Surveillance, Epidemiology, and End Results (SEER) database, and further estimated the predictive performance of the nomogram by internal and external validations.

Material and Methods

Data Sources and Study Design

The SEER database records information about demographics, primary tumor site, tumor morphology, stage at diagnosis, the first course of treatment, and vital status after follow-up for the US population. In this retrospective cohort study, data on cervical cancer cases were obtained from the SEER 18 Regs Custom Data (with additional treatment fields) of the National Cancer Institute (http://seer.cancer.gov/) between 2010 and 2016. The diagnosis of cervical cancer was confirmed through the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), primary site codes C53.0, C53.1, C53.8, and C53.9, combined with histology codes, which are provided in Supplementary Material. Postoperative distant metastasis was defined through the cancer metastasis at distant site [CS met at DX, https://staging.seer.cancer.gov/cs/input/02.05.50/lung/mets/?(-view_schema=--lung--)]. Furthermore, inclusion criteria were: (1) the age of patients was ≥18 years; (2) baseline data were complete; (3) patients were treated with surgery. Exclusion criteria were: (1) the tumor grade was unknown; (2) data on T and N stages were incomplete; (3) the tumor size was unknown; (4) information of tumor metastasis was missing.

Data Extraction

The following data were extracted from the SEER database: age at diagnosis, histologic type (squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and others), tumor grade, treatment (surgery, surgery+chemotherapy, surgery+radiotherapy, and surgery+radiotherapy+chemotherapy), T stage, N stage, tumor size, first malignant primary, regional nodes, regional nodes positive, and CS metastasis at DX. In this study, the outcome was postoperative distant metastasis, which was confirmed by the “CS mets at DX”, with “Yes” suggesting the occurrence of postoperative distant metastasis.

Development and Validation of the Nomogram

To develop and validate the nomogram, all the enrolled patients were randomly divided into 2 sets by random number generation: training (n=4495) and testing (n=1926) sets. For the training set, factors that were statistically different between non-metastasis and metastasis groups through difference analysis were included in multivariate stepwise logistic regression analysis (rms package) to identify independent predictors for postoperative distant metastasis in patients with cervical cancer. Based on the identified predictors, the nomogram was constructed to predict postoperative distant metastasis for cervical cancer.

The testing set was utilized for interval validation of the nomogram, and external validation was conducted using clinical data from 561 Chinese cervical cancer patients who developed distant metastasis during postoperative follow-ups from the Meizhou People’s Hospital between 3 February 2015 and 1 July 2020, which was approved by the Ethics Committee of the Meizhou People’s Hospital (Huangtang Hospital), Meizhou.
were treated with surgery only, 164 (3.65%) with surgery and
ed). Of the 4495 patients in the training cohort, 2454 (54.59%)
Grade III (poorly differentiated), and Grade IV (undifferentiat
I (well differentiated), Grade II (moderately differentiated),
1975-2018”, cervical cancers have 4 tumor grades: Grade
The tumor grades were: I (2033/45.23%), II (1486/33.06%),
943 (20.98%) patients with other histopathologic cell types.
226 (5.03%) patients with adenosquamous carcinoma, and
783 (17.42%) patients with adenocarcinoma, 476 (10.67%)
years, and there were 2543 (56.57%) patients with squamous
hort. In the training cohort the average age was 47.15±12.42
A total of 6421 patients were enrolled in this study, with 4495
patients in the training cohort and 1926 in the testing co
were treated with surgery only, 449 (9.96%) with surgery and
482 (10.72%) with surgery and radiotherapy, and 1395 (31.03%)
with surgery, radiotherapy, and chemotherapy. There were 190 (4.23%)
patients with postoperative metastasis and 4305 (95.77%) without postoperative metas-
tasis (Figure 1, Table 1).

Identification of Predictive Factors Based on the Training
Set
Age, histologic type, tumor grade, number of lymph nodes, T
stage, N stage, treatment, tumor size (>2 cm), first malignant
primary, and lymph node positivity were significantly differ-
tent between patients with and without postoperative distant
metastasis in the training set according to univariate analysis
(P<0.05) (Table 2). However, only histologic type, T stage,
treatment, tumor size, and positive lymph node were identi-
ted to be significantly associated with postoperative metas-
tasis in multivariate analysis (P<0.05) (Figure 2).

Nomogram Construction and Evaluation
Based on the predictive factors, including histologic type, T
stage, treatment, tumor size, and lymph node positivity, the
prediction model was constructed: Y = -5.761 + 0.746 × histologic
type (adenosquamous carcinoma) + 0.879 × histologic type (oth-
er) + 0.930 × T stage (T2) + 1.876 × T stage (T3) + 1.923 × T stage
(T4) + 2.378 × treatment (surgery and chemotherapy) + 0.759 ×
treatment (surgery and radiotherapy) + 0.723 × treatment (sur-
gery, radiotherapy, and chemotherapy) + 0.769 × tumor size
(≥4 cm) + 1.272 × lymph node positivity (yes). The nomogram
prediction of postoperative distant metastasis was present-
ed (Figure 3), with an AUC of 0.866 (95% CI: 0.844 to 0.888)
(Figure 4). These results showed that the nomogram had good
predictive ability in the training cohort.

Nomogram Validation
Internal and external validations were conducted to assess the
predictive value of the nomogram. In the internal validation,
the AUC for the predictive nomogram was 0.847 (95% CI: 0.807
to 0.888) (Figure 5A), and the chi-squares of the McNemar’s
and Hosmer-Lemeshow tests were 0.039 (P>0.05) and 11.292
(P>0.05), respectively (Table 3). Meanwhile, a calibration curve
for the predictive nomogram was drawn in the internal vali-
dation cohort, indicating good calibration (Figure 5B). The
results of internal validation indicated that the nomogram had
good discrimination and calibration abilities. In the external
validation, the AUC for the predictive nomogram was 0.626
(95% CI: 0.548 to 0.704) (Figure 6A), and the chi-squares of the Mc-
Nemar’s and Hosmer-Lemeshow tests were 111.484 (P<0.05)
and 316.53 (P<0.05), respectively (Table 4). Meanwhile, a cali-
bration curve for the predictive nomogram was drawn in the ex-
ternal validation cohort, indicating poor calibration (Figure 6B).
Patients with cervical cancer (n=20343)
Excluded (n=13922)
Without surgery therapy

Patients after surgical therapy (n=15907)
Excluded (n=4436)
Without information of cancer metastasis (n=135)
Without information of tumor grade (n=188)
Without information of tumor size (n=1583)
Without information of lymph node positive (n=6)
Without information of age (n=193)

Included (n=6421)

Training set (n=4495):
Metastasis (n=190)
Non-metastasis (n=4305)

Testing set (n=1926):
Metastasis (n=73)
Non-metastasis (n=1853)

Table 1. Baseline characteristics of study populations [n (%)/M (Q₁, Q₃)].

| Variables                      | Training set (n=4495) | Internal validation set (n=1926) |
|--------------------------------|-----------------------|----------------------------------|
| Age at diagnosis (years), Mean±SD | 47.15±12.42           | 46.63±12.29                      |
| Histologic type, n (%)          |                       |                                  |
| Squamous cell carcinoma         | 2543 (56.57)          | 1050 (54.52)                     |
| Adenocarcinoma                  | 783 (17.42)           | 368 (19.11)                      |
| Adenosquamous carcinoma         | 226 (5.03)            | 93 (4.83)                        |
| Others                          | 943 (20.98)           | 415 (21.55)                      |
| Grade, n (%)                    |                       |                                  |
| I                              | 2033 (45.23)          | 827 (42.94)                      |
| II                             | 1486 (33.06)          | 646 (33.54)                      |
| III                            | 115 (2.56)            | 48 (2.49)                        |
| IV                             | 861 (19.15)           | 405 (21.03)                      |
| Treatment, n (%)                |                       |                                  |
| Surgery                        | 2454 (54.59)          | 1012 (52.54)                     |
| Surgery + chemotherapy          | 164 (3.65)            | 66 (3.43)                        |
| Surgery + radiotherapy          | 482 (10.72)           | 211 (10.96)                      |
| Surgery + radiotherapy + chemotherapy | 1395 (31.03)  | 637 (33.07)                      |
| CS met at DX, n (%)             |                       |                                  |
| No                             | 4305 (95.77)          | 1853 (96.21)                     |
| Yes                            | 190 (4.23)            | 73 (3.79)                        |

SD – standard deviation; CS met at DX – cancers metastasis at distant site.
Table 2. Results of univariate analysis in the training set.

| Variables                        | Training set | Statistics |  P  |
|----------------------------------|--------------|------------|-----|
|                                  | Non-metastasis (n=4305) | Metastasis (n=190) |      |
| **Age at diagnosis (years), Mean±SD** | 46.96±12.39 | 51.28±12.38 | t=−4.700 | <0.001 |
| **Histologic type, n (%)**       |              |            |      |
| Squamous cell carcinoma          | 2460 (57.14) | 83 (43.68) | χ²=30.512 | <0.001 |
| Adenocarcinoma                   | 758 (17.61)  | 25 (13.16) |      |      |
| Adenosquamous carcinoma           | 209 (4.85)   | 17 (8.95)  |      |      |
| Other                            | 878 (20.39)  | 65 (34.21) |      |      |
| **Grade, n (%)**                 |              |            |      |
| I                                | 1968 (45.71) | 65 (34.21) |      |      |
| II                               | 1383 (32.13) | 103 (54.21) |      |      |
| III                              | 104 (2.42)   | 11 (5.79)  |      |      |
| IV                               | 850 (19.74)  | 11 (5.79)  |      |      |
| **T stage, n (%)**               |              |            |      |
| T1                               | 3552 (82.51) | 65 (34.21) |      |      |
| T2                               | 616 (14.31)  | 67 (35.26) |      |      |
| T3                               | 115 (2.67)   | 46 (24.21) |      |      |
| T4                               | 22 (0.51)    | 12 (6.32)  |      |      |
| **N stage, n (%)**               |              |            |      |
| N0                               | 3645 (84.67) | 65 (34.21) |      |      |
| N1                               | 660 (15.33)  | 125 (65.79) |      |      |
| **Treatment, n (%)**             |              |            |      |
| Surgery                          | 2430 (56.45) | 24 (12.63) |      |      |
| Surgery+chemotherapy              | 118 (2.74)   | 46 (24.21) |      |      |
| Surgery+radiotherapy              | 465 (10.80)  | 17 (8.95)  |      |      |
| Surgery+radiotherapy+chemotherapy | 1292 (30.01) | 103 (54.21) |      |      |
| **Tumor size (cm), n (%)**       |              |            |      |
| <4                               | 3245 (75.38) | 61 (32.11) |      |      |
| ≥4                               | 1060 (24.62) | 129 (67.89) |      |      |
| **First malignant primary, n (%)** |             |            |      |
| No                               | 204 (4.74)   | 16 (8.42)  |      |      |
| Yes                              | 4101 (95.26) | 174 (91.58) |      |      |
| **Number of lymph node, M (Q₁, Q₃)** | 13.00 (0.00, 22.00) | 5.00 (0.00, 16.00) | Z=-4.874 | <0.001 |
| **Regional nodes positive, n (%)** |            |            |      |
| No                               | 2615 (60.74) | 36 (18.95) |      |      |
| Yes                              | 1690 (39.26) | 154 (81.05) |      |      |

SD – standard deviation; M – median.
### Variables

| Variables                  | OR     | 95% CI      | P     |
|----------------------------|--------|-------------|-------|
| **Histological type**      |        |             |       |
| Squamous cell carcinoma    | Ref    |             |       |
| Adenocarcinoma             | 1.475  | 0.893-2.437 | 0.129 |
| Adenosquamous carcinoma    | 2.108  | 1.137-3.908 | 0.018 |
| Other                      | 2.409  | 1.657-3.504 | <0.001|
| **T stage**                |        |             |       |
| T1                         | Ref    |             |       |
| T2                         | 2.535  | 1.694-3.792 | <0.001|
| T3                         | 6.528  | 4.003-10.644| <0.001|
| T4                         | 6.843  | 2.965-15.791| <0.001|
| **Treatment**              |        |             |       |
| Surgery                    | Ref    |             |       |
| Surgery+chemotherapy       | 10.780 | 5.961-19.495| <0.001|
| Surgery+radiotherapy       | 2.137  | 1.097-4.163 | 0.026 |
| Surgery+radiotherapy+chemotherapy | 2.061 | 1.236-3.438 | 0.006 |
| **Tumor size**             |        |             |       |
| <4                         | Ref    |             |       |
| ≥4                         | 2.158  | 1.488-3.129 | <0.001|
| **Lymph node positive**    |        |             |       |
| No                         | Ref    |             |       |
| Yes                        | 3.567  | 2.377-5.354 | <0.001|

**Figure 2.** Results of multivariate analysis. R software (version 4.0.2, R Foundation for Statistical Computing) was used for figure creation.

**Figure 3.** Nomogram prediction of postoperative metastasis. R software (version 4.0.2, R Foundation for Statistical Computing) was used for figure creation.
These findings of the external validation suggested that the discrimination and calibration abilities of the nomogram were poor in the Chinese cohort. To further assess the applicability of the nomogram in the Chinese population, the nomogram’s predictive ability was evaluated in subgroups stratified by age, histologic type, T stage, treatment, tumor size, and lymph node positivity. We found that the AUC of the nomogram for cervical cancer patients with adenocarcinoma was 0.811 (95% CI: 0.618 to 1.000) (Table 5). These results implied that the nomogram exhibited good performance in predicting postoperative distant metastasis among cervical cancer patients with adenocarcinoma.

**Discussion**

Early diagnosis and surgical treatment have been advocated for cervical cancer patients. However, the occurrence of postoperative distant metastasis remains a complex problem, and nomograms to accurately estimate postoperative distant metastasis for cervical cancer await more exploration. The present

---

**Table 3.** Results of the McNemar’s test in the internal validation set.

| Predicted outcomes | Actual outcomes | McNemar | P       |
|--------------------|-----------------|---------|---------|
|                    | Non-metastasis  | Metastasis | χ²      |         |
| Non-metastasis     | 1802 (97.14)    | 53 (2.86)  | 0.039   | 0.845   |
| Metastasis         | 51 (71.83)      | 20 (28.17) |         |         |
A novel prediction tool for the risk of postoperative distant metastasis in cervical cancer patients was developed and validated. The tool includes histologic type, T stage, treatment, tumor size, and positive lymph node as predictors. A nomogram was established with an AUC of 0.866, showing very good predictive ability in the internal cohort. However, external validation showed poor discrimination and calibration in the Chinese cohort, but good predictive ability for adenocarcinoma patients. Adjuvant treatment, including radiotherapy, chemotherapy, or radiotherapy combined with chemotherapy, increases the risk of metastasis. Chemotherapy inhibits normal cells, forming a more suitable microenvironment for metastasis. M2-type macrophages facilitate tumor growth and angiogenesis, promoting metastasis. High-dose ionizing radiation promotes metastasis and invasion of cancer cells via inducing epithelial-mesenchymal transition (EMT), hindered by low-dose IR promoting capillary formation.

### Table 4. Results of the McNemar's test in the external validation set.

| Predicted outcomes | Actual outcomes | McNemar | P |
|--------------------|----------------|---------|---|
|                    | Non-metastasis | Metastasis | χ² | <0.001 |
| Non-metastasis     | 351 (94.35)    | 21 (5.65)   | 111.484 |     |
| Metastasis         | 165 (87.30)    | 24 (12.70)   |       |     |

### Figure 6. The (A) ROC curves and (B) calibration curve of the external validation set. R software (version 4.0.2, R Foundation for Statistical Computing) was used for figure creation.
cells induced by activation of the Akt-pathway, thus promoting tumor metastasis [35]. Administering vascular endothelial growth factor (VEGF) receptor-tyrosine kinase inhibitors immediately before IR exposure can prevent low-dose IR from promoting tumor growth and metastasis [36]. Beyond that, patients receiving surgery and chemotherapy or radiotherapy should have a regular follow-up after surgery.

Tumor size, T stage, and histologic type were independent predictors of postoperative distant metastasis in cervical cancer patients. A previous study indicated that a tumor size larger than 4 cm increased the risk of recurrence in cervical cancer patients [37]. Our results indicated that tumor size ≥4 cm was a predictor of increased distant metastasis in cervical cancer patients after surgery. Generally, a larger tumor with an adequate blood supply has longer growth time, increasing the possibility of lymph node metastasis, local infiltration, and distant metastasis, and the tumor can be prone to recurrence and distant metastasis after surgery. It has been proven that with the increase of tumor size, the number of tumor cells in the peripheral blood increases [38]. A study revealed that the number of tumor cells in bone marrow was positively correlated with tumor size in patients with cervical cancer [39]. From the perspective of the patients’ condition, positive lymph node status was determined as an independent predictor of distant metastasis in cervical cancer patients after surgery. Lymph node metastasis has been confirmed to be a risk factor in cervical cancer patients who underwent surgery [40,41], which confirmed our result that lymph node positivity was a predictor of the increased risk of distant metastasis. Although previous studies have developed several prediction models for the distant metastasis of cervical cancer, our research supplements these studies. Wang et al incorporated log of odds between the number of positive lymph nodes and the number of negative lymph nodes (LODDS) in establishing a prognostic nomogram for cervical cancer patients after surgery [42]. However, they focused on overall survival of patients with cervical cancer. In the present study, we specifically constructed a nomogram to predict postoperative distant metastasis of cervical cancer, with AUCs of 0.866 and 0.847 in the training and validation cohorts, respectively. Future studies

| Variables | External validation set (n=561) | AUC (95% CI) |
|-----------|---------------------------------|--------------|
| Age       |                                 |              |
| <60       | 463                             | 0.655 (0.570-0.740) |
| ≥60       | 98                              | 0.504 (0.314-0.695) |
| Histologic type |                        |              |
| Squamous cell carcinoma | 467 | 0.636 (0.553-0.718) |
| Adenocarcinoma | 72 | 0.811 (0.618-1.000) |
| Adenosquamous carcinoma | 9 | NA |
| Others    | 13                              | 0.636 (0.369-0.904) |
| T stage   |                                 |              |
| T1        | 361                             | 0.598 (0.472-0.724) |
| T2        | 195                             | 0.473 (0.352-0.594) |
| Treatment |                                 |              |
| Surgery   | 245                             | 0.670 (0.515-0.824) |
| Surgery+chemotherapy | 11 | 0.639 (0.272-1.000) |
| Surgery+radiotherapy | 183 | 0.537 (0.391-0.683) |
| Surgery+radiotherapy+chemotherapy | 122 | 0.585 (0.450-0.720) |
| Tumor size |                                 |              |
| <4        | 473                             | 0.650 (0.562-0.737) |
| ≥4        | 88                              | 0.548 (0.285-0.812) |
| Regional nodes positive |              |              |
| No        | 22                              | NA           |
| Yes       | 538                             | 0.630 (0.550-0.710) |

AUC – area under the curve; CI – confidence interval; NA – not available.
can take LODDS into consideration for predicting postoperative distant metastasis among cervical cancer patients. A model to predict distant metastasis in cervical cancer patients was developed by Liu et al [43], and the differences between their model and our model are as follows. On the one hand, regarding subjects, cervical cancer patients treated with definitive radiotherapy were included in the study of Liu et al. Although radiotherapy has been recommended as a standard treatment for patients with advanced cervical cancer, most patients with cervical cancer undergo surgery, indicating that distant metastasis in many patients could not be predicted by the model constructed by Liu et al, while the nomogram we constructed could be applied to more patients. On the other hand, external validation that provides essential and robust evidence was performed to assess the application of the nomogram developed in our study. Further, Je et al also developed a scoring system among 223 node-positive cervical cancer patients to predict postoperative distant metastasis for Korean patients with uterine cervical carcinoma. This model displayed an internally validated concordance index (C-index) of 0.71 and an externally validated C-index of 0.65 [18]. In 2017, the nomogram proposed by Je et al was subjected to external validation by Yoon et al in 109 Korean cervical cancer patients, showing with a C-index of 0.597 [19]. In the present study, apart from the larger sample size used for nomogram development, our nomogram was first developed and internally validated with the US population and externally verified in the Chinese population, which demonstrated an AUC of 0.847 in the internal validation and an AUC of 0.811 for cervical cancer patients with adenocarcinoma in the external validation, indicating great applicability of the nomogram to both the US population and the specific Chinese population. Moreover, Je et al’s nomogram focused on the patients who received radiotherapy after surgery, whereas our nomogram focused on patients who underwent surgery only, surgery+chemotherapy, surgery+radiotherapy, and surgery+radiotherapy+chemotherapy, suggesting that our model can be used more widely. Lee et al also developed a scoring system among 223 node-positive cervical cancer patients from a single center in Korea to predict the risk of postoperative distant recurrence, with an internally validated C-index of 0.777 [14]. By contrast, the present study utilized nationally representative data in the US to establish the predictive nomogram, and then carried out external validation to assess the performance of the model among Chinese patients in urgent need of postoperative distant metastasis prediction.

A strength of the present study is its relatively large sample size. Moreover, external validation of the predictive nomogram was carried out. However, our research indicated that the nomogram might not be applied to the Chinese population, possibly due to differences between Chinese and US populations. Our study also has several limitations. First, this was a retrospective study based on the SEER database. Second, the prediction model was validated in only 1 hospital. Patients from different institutions or ethnicities are needed to conduct external validations. Third, owing to the limited data collected, the effects of different surgical treatments and chemotherapy drugs on postoperative distant metastasis could not be evaluated, and further studies are required to explore the relationships between them.

**Conclusions**

Our nomogram had good predictive performance for postoperative distant metastasis in patients with cervical cancer based on 6421 participants from the SEER database, which may serve as a reference for clinicians to identify cervical cancer patients with a high risk of postoperative distant metastasis early to provide individualized therapy. However, whether the nomogram is applicable to other populations remains to be determined.

**Declaration of figures’ authenticity**

All figures submitted have been created by the authors, who confirm that the images are original with no duplication and have not been previously published in whole or in part.

**Supplementary Material**

The diagnosis of cervical cancer was confirmed through the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), primary site codes C53.0, C53.1, C53.8, C53.9, combined with histology codes 8000, 8001, 8010, 8012, 8013, 8015, 8020, 8022, 8033, 8041, 8042, 8045, 8046, 8050, 8051, 8052, 8070, 8071, 8072, 8073, 8074, 8075, 8076, 8082, 8083, 8084, 8094, 8098, 8120, 8123, 8130, 8140, 8144, 8200, 8210, 8240, 8244, 8246, 8255, 8260, 8261, 8262, 8263, 8310, 8313, 8323, 8380, 8382, 8384, 8410, 8441, 8460, 8461, 8480, 8841, 8482, 8490, 8500, 8542, 8550, 8570, 8574, 8720, 8800, 8801, 8802, 8805, 8890, 8896, 8900, 8910, 8912, 8920, 8931, 8933, 8935, 8950, 8963, 8980, 9044, 9080, 9100, 9110, 9473, 9581.
1. Castle PE, Einstein MH, Sahasrabudhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. Cancer J Clin. 2021;71:505-26
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394-424
3. Lyu Y, Ding L, Gao T, et al. Influencing factors of high-risk human papillomavirus infection and dna load according to the severity of cervical lesions in female coal mine workers of China. J Cancer. 2019;10:5764
4. Burki TK. Outcomes after minimally invasive surgery in cervical cancer. Lancet Oncol. 2018;19:e674
5. Huang B-x, Fang F. Progress in the study of lymph node metastasis in early-stage cervical cancer. Curr Med Sci. 2018;38:567-74
6. Zhang X, Sheng X, Yan Y. Clinical pathological factors of radiosensitivity in patients with cervical cancer treated with radiotherapy. Chin J Cancer Prev Treat. 2011;18:1204-7
7. Alfsen GC, Kristensen BG, Skovlund E, et al. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: A population based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer. 2001;92:2471-83
8. Liu MT, Hsu JC, Liu WS, et al. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and postoperative adjuvant therapy. Eur J Cancer Care (Eng). 2008;17:174-81
9. Kim HI, Rhee WJ, Choi SH, et al. Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer. Radiat Oncol J. 2015;33:126-33
10. Kim MK, Jo H, Kong HJ, et al. Postoperative nomogram predicting risk of recurrence after radical hysterectomy for early-stage cervical cancer. Int J Gynecol Cancer. 2010;20:1581-86
11. Gülsener V, Kocaer M, Çakır İ, et al. Postoperative nomogram for the prediction of disease-free survival in lymph node-negative stage I-IIA cervical cancer patients treated with radical hysterectomy. J Obstet Gynaecol. 2020;40:699-704
12. Je HU, Han S, Kim YS, et al. Risk prediction model for disease-free survival in women with early-stage cervical cancers following postoperative (chemo)radiotherapy. Tumori. 2018;104:105-10
13. Tang X, Guo C, Liu S, et al. A novel prognostic nomogram utilizing the 2018 FIGO staging system for cervical cancer: A large multicenter study. Int J Gynaecol Obstet. 2021;155:86-94
14. Lee Y-J, Kim D-Y, Lee S-W, et al. A radiomics nomogram for the preoperative prediction of lymph node metastasis in bladder cancer. Clin Cancer Res. 2017;23:6904-11
15. Guo CG, Zhao DB, Liu Q, et al. A nomogram to predict lymph node metastasis in patients with early gastric cancer. Oncotarget. 2017;8:12203
16. D’Alessio C, Scala S, Sozzi G, et al. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol. 2020;60:351-61
17. Guruvayoorappan C. Tumor versus tumor-associated macrophages: How hot is the link? Integr Cancer Ther. 2008;7:90-95
18. Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: Implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol. 2003;163:1233-43
19. Gocheva V, Wang H-W, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241-55
20. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64:7022-29
21. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65:5278-83
22. Du R, Lu KV, Petitch T, et al. HiFIx induces the recruitment of bone marrow-derived vascular muralcular cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13:206-20
23. Su S, Liu Q, Chen J, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell.2014;25:605-20
24. Djikgraaf EM, Heusinkveld M, Timmers B, et al. Chemotherapy alters monocyte phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16:10
25. Sundahl N, Duprez F, Ost P, et al. Effects of radiation on the metastatic process. Mol Med. 2018;24:1-20
26. Madani I, De Neve W, Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer. 2008;95:292-300
27. Lee SY, Jeong EK, Ju MK, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16:10
28. Rüegg C, Monnier Y, Kuenen F, Imaizumi N. Radiation-induced modifications of the tumor microenvironment promote metastasis. Bull Cancer. 2011;98:E47-57
29. Sofia Vala I, Martins LR, Imaizumi N, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 2010;5:e11222
30. Turan T, Yildirim BA, Tulunay G, et al. Prognostic effect of different cut-off values (20 mm, 30 mm and 40 mm) for clinical tumor size in FIGO stage IB cervical cancer. Surg Oncol. 2010;19:106-13
31. Viswanathan AN, Erickson B, Gaffney DK, et al. Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014;90:320-28
32. Attaleb M, Khayatti M, Benhacer L, et al. Status of p16INK4A and E-cadherin gene promoter methylation in moroccan patients with cervical carcinoma. Oncol Res. 2009;18:185-92
33. Wertheim MS, Hakes T, Daghhestani A, et al. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 1985;3:912-16
34. Uno T, Ito H, Itami J, et al. Postoperative radiation therapy for stage IB-IIA carcinoma of the cervix with poor prognostic factors. Anticancer Res. 2000;20:2235-39
35. Wang C, Yang C, Wang W, et al. A prognostic nomogram for cervical cancer after surgery from SEER database. J Cancer. 2018;9:1923-28
36. Liu X, Meng Q, Wang W, et al. Predictors of distant metastasis in patients with cervical cancer treated with definitive radiotherapy. J Cancer. 2019;10:3967

Indexing in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]